Kiora Pharmaceuticals Inc entered a material agreement; made a public disclosure
SEC 8-KRead source ↗
Kiora Pharmaceuticals Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 45% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Kiora Pharmaceuticals Inc's latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 6 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 63% and a beta of 1.1 against the S&P 500.
Latest results
- Earnings per share
- -$0.34 against an average estimate of -$0.62: beat by 45.2%
- Share reaction
- +0.8% in the first session after the results on August 7, 2026, against +0.6% for the S&P 500
Price chart
- 1 day+4.5%
- 1 week-26.2%
- 1 month-36.3%
- This year-17.3%
- 1 year-29.4%
- 5 years-99.8%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 7, 2026
- Next results (est.)
- November 6, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Agreement
- Leadership
Kiora Pharmaceuticals Inc announced a director or officer change; made a public disclosure
SEC 8-KRead source ↗ - Agreement
Kiora Pharmaceuticals Inc entered a material agreement; made a public disclosure
SEC 8-KRead source ↗ - Results
Kiora Pharmaceuticals Inc reported results
SEC 8-KRead source ↗
No model value for Kiora Pharmaceuticals Inc at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Kiora Pharmaceuticals Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.11 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Kiora Pharmaceuticals Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.67 | +36% | — | 0% |
| Next | −$1.41 | +16% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −37.2% on 90 days ago. In the last 30 days, 1 analyst raised Kiora Pharmaceuticals Inc's forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.66 | −$1.97 |
| 60 days ago | −$2.66 | −$1.97 |
| 30 days ago | −$2.66 | −$1.97 |
| 7 days ago | −$2.66 | −$1.97 |
| Now | −$1.67 | −$1.41 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.62 | −$0.34 | +45.2% |
| Mar 2026 | −$0.71 | −$0.58 | +18.3% |
| Sept 2025 | −$0.72 | $0.01 | +101.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 0.1% of tradable shares
- Days to cover
- 0.29 at average volume
- Short interest, 1 month
- +4% to October 15, 2026
- Held by institutions
- 36% of shares
- Held by insiders
- 8.9% of shares
- Employees
- 13 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| KPRX | −69% | −94% | −85% | −30% | −40% | −17% |
| Industry peers (median) | −35% | −56% | −17% | −28% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| KPRX | 25% | 25% | 50% | 42% | 25% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| KPRX | −89% | −96% | −93% | −60% | −55% | −46% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from November 5, 2015 to October 30, 2026. Getting back needed a 1422592% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $1.56 – $2.86
- From 52-week high
- −43.0%
- vs 50-day average
- −34.3%
- vs 200-day average
- −32.4%
- Volatility (1 year)
- 63%
- Beta vs S&P 500
- 1.13
Share price after results
- Next day
- 8 up, 4 down typical move ±2.6%
- After a week
- 5 up, 7 down typical move ±8.3%
- After a month
- 7 up, 5 down typical move ±8.3%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 7, 2026 | +0.8% | +0.6% | −0.4% | −2.0% |
| May 8, 2026 | −1.6% | +1.1% | +2.0% | +5.7% |
| March 25, 2026 | −4.4% | −1.2% | −5.3% | +14.1% |
| November 7, 2025 | +0.4% | +1.7% | −6.9% | −11.2% |
| August 8, 2025 | +2.5% | +0.6% | +22.6% | +10.0% |
| May 9, 2025 | +2.2% | +3.2% | +3.5% | +7.1% |
| March 25, 2025 | −6.6% | −1.0% | −8.4% | 0.0% |
| November 8, 2024 | +4.7% | +0.5% | −7.8% | +2.0% |
| August 9, 2024 | −0.6% | +0.5% | +15.3% | +7.4% |
| May 10, 2024 | +5.2% | +0.1% | +17.5% | +8.6% |
| March 25, 2024 | +1.7% | −0.5% | −2.0% | −15.7% |
| November 9, 2023 | +1.0% | +0.8% | −7.8% | −15.6% |
Fundamentals
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 6, 2026 estimated from the company's past filing pattern, not announced
- August 7, 2026
- May 8, 2026
- March 25, 2026
- November 7, 2025
- August 8, 2025
- May 9, 2025
Recent SEC filings
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- S-3 S-3
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Kiora Pharmaceuticals Inc in brief
- What does Kiora Pharmaceuticals Inc do?
- Kiora Pharmaceuticals Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Kiora Pharmaceuticals Inc's stock ticker?
- Kiora Pharmaceuticals Inc trades under the ticker KPRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- When is Kiora Pharmaceuticals Inc's next earnings date?
- Around November 6, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kiora Pharmaceuticals Inc announces its own schedule.
Follow research on Kiora Pharmaceuticals Inc
New research on the companies we cover arrives in the weekly email. Free, one email a week.